During clinical trials, a number of fully characterized molecules are dropped along the way because they do not provide enough benefit for the patient. Some of them show limited side effects and might be of great use for other applications. AS1411 is a nucleolin-targeting aptamer that underwent phase II clinical trials as anticancer agent. Here, we show that AS1411 exhibits extremely potent antiviral activity and is therefore an attractive new lead as anti-HIV agent.< Leer menos

Palabras clave en inglés

Anti-HIV Agents

Antineoplastic Agents

Aptamers

Nucleotide

Cell Line

Cell Proliferation

HIV-1

Humans

Oligodeoxyribonucleotides

Ver/Abrir

Metadatos

Compartir este ítem

Licencia de uso del documento

Anticancer molecule AS1411 exhibits low nanomolar antiviral activity against HIV-1.

Idioma

Este ítem está publicado en

Resumen en inglés

Palabras clave en inglés

URI

DOI

Centros de investigación